Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries
Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries
Biocon Biologics on Monday said it has completed integration of the acquired Viatris' biosimilar business in 120 countries, a year ahead of schedule.
The company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris.
With the completion of this significant milestone, Biocon Biologics is now a fully integrated ‘lab to market’ biosimilars company committed to serving millions of patients across the globe.
Around 70 emerging markets were integrated in July, the North America business transitioned in September and the European business in November.
Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models.
Biocon Biologics will now have a commercial footprint across 120 countries with a direct presence in the US, Canada, Europe and 9 key emerging market countries, namely India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.
A direct presence in these markets will enable the Company to get closer to patients and strengthen its relationships with prescribers and payers. It will also allow Biocon Biologics to expand its patient reach and generate significant savings for healthcare systems.
All Viatris' biosimilar brands, including Ogivri & Hertraz (trastuzumab), Abevmy (bevacizumab), Fulphila (pegfilgrastim), Hulio (adalimumab), Nepexto (etanercept),
